Tocqueville Asset Management’s Myriad Genetics MYGN Stock Holding History

Tocqueville Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,000	Closed	-$333K	–	773
2019 Q2	$333K	Sell	12,000 -8,000	-40%	-$226K	﹤0.01%	663
2019 Q1	$664K	Hold	20,000	–	–	0.01%	536
2018 Q4	$581K	Hold	20,000	–	–	0.01%	533
2018 Q3	$920K	Sell	20,000 -15,053	-43%	-$669K	0.01%	516
2018 Q2	$1.31M	Sell	35,053 -8	-0%	-$270	0.02%	469
2018 Q1	$1.04M	Hold	35,061	–	–	0.01%	504
2017 Q4	$1.2M	Sell	35,061 -38	-0.1%	-$1.28K	0.01%	490
2017 Q3	$1.27M	Hold	35,099	–	–	0.01%	503
2017 Q2	$907K	Sell	35,099 -10,000	-22%	-$212K	0.01%	517
2017 Q1	$866K	Buy	+45,099	New	+$799K	0.01%	512

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tocqueville Asset Management's MYGN Position: Q3 2019 in Review

Tocqueville Asset Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 12,000 shares — an estimated $333K sold.

Tocqueville Asset Management first reported a position in MYGN in Q1 2017 and held it in 10 quarters. The position peaked at $1.31M in Q2 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Tocqueville Asset Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Tocqueville Asset Management sold 12,000 Myriad Genetics shares in Q3 2019, an estimated $333K.
Tocqueville Asset Management first reported a position in Myriad Genetics in Q1 2017 and held it in 10 quarters.
Tocqueville Asset Management's Myriad Genetics position peaked at $1.31M in Q2 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Tocqueville Asset Management's 13F filing for Q3 2019, filed 31 Oct 2019.